2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Sedentary Behavior
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Neutropenia
1
Multiple Endocrine Neoplasia Type 1
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Intraabdominal Infections
1
Insulin Resistance
1
Influenza, Human
1
Inflammation
1
Infections
1
Hypokalemia
1
Hypertension
1
Hyperlipidemias
1
Hyperglycemia
1
Hyperaldosteronism
1
Interventions
Levetiracetam
6
Cannabidiol
5
perampanel
2
Tranexamic Acid
2
Standard of Care
2
Everolimus
2
ziprasidone
1
enzalutamide
1
Zolpidem
1
Warfarin
1
Vigabatrin
1
Vecuronium Bromide
1
Vancomycin
1
Tobramycin
1
Temozolomide
1
Spironolactone
1
Solutions
1
Sodium Chloride
1
Sevelamer
1
Saline Solution
1
Rocuronium
1
Remifentanil
1
Propofol
1
Pregabalin
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Nifedipine
1
Nafcillin
1
Molindone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Seizures
×
ziprasidone
×
Clear all
NCT01431326
2023-09-06
PTN_POPS
Duke University
Completed
3,520 enrolled